HK12595A - Process for the preparation of solid nifedipine formulations of high bioavailability and with sustained effect, and formulations thus obtained - Google Patents

Process for the preparation of solid nifedipine formulations of high bioavailability and with sustained effect, and formulations thus obtained

Info

Publication number
HK12595A
HK12595A HK12595A HK12595A HK12595A HK 12595 A HK12595 A HK 12595A HK 12595 A HK12595 A HK 12595A HK 12595 A HK12595 A HK 12595A HK 12595 A HK12595 A HK 12595A
Authority
HK
Hong Kong
Prior art keywords
formulations
polyethylene glycol
active substance
solution
micronized
Prior art date
Application number
HK12595A
Other languages
English (en)
Inventor
Massimo Calanchi
Piergiorgio Rossi
Original Assignee
Eurand Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurand Int filed Critical Eurand Int
Publication of HK12595A publication Critical patent/HK12595A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heat Treatment Of Sheet Steel (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
HK12595A 1985-10-15 1995-01-26 Process for the preparation of solid nifedipine formulations of high bioavailability and with sustained effect, and formulations thus obtained HK12595A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT22494/85A IT1187751B (it) 1985-10-15 1985-10-15 Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute

Publications (1)

Publication Number Publication Date
HK12595A true HK12595A (en) 1995-02-03

Family

ID=11197023

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12595A HK12595A (en) 1985-10-15 1995-01-26 Process for the preparation of solid nifedipine formulations of high bioavailability and with sustained effect, and formulations thus obtained

Country Status (18)

Country Link
US (1) US4880623A (xx)
EP (1) EP0220760B1 (xx)
JP (1) JPH0811731B2 (xx)
KR (1) KR940006320B1 (xx)
AT (1) ATE66367T1 (xx)
AU (1) AU590622B2 (xx)
CA (1) CA1280976C (xx)
DE (1) DE3680989D1 (xx)
DK (1) DK168691B1 (xx)
ES (1) ES2040209T3 (xx)
FI (1) FI87424C (xx)
GR (1) GR3003150T3 (xx)
HK (1) HK12595A (xx)
IT (1) IT1187751B (xx)
NO (1) NO172168C (xx)
NZ (1) NZ217841A (xx)
PT (1) PT83522B (xx)
ZA (1) ZA867767B (xx)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
US5215752A (en) * 1988-03-17 1993-06-01 Vectorpharma International S.P.A. Pharmaceutical tablets and capsule granulates of scleroglucan and active substance
US5028433A (en) * 1988-11-30 1991-07-02 Banyu Pharmaceutical Co., Ltd. Readily absorbable drug formulation of NB-818
GB8903328D0 (en) * 1989-02-14 1989-04-05 Ethical Pharma Ltd Nifedipine-containing pharmaceutical compositions and process for the preparation thereof
HU203041B (en) * 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
GB9025251D0 (en) * 1990-11-20 1991-01-02 Solomon Montague C Nifedipine dosage forms
US5145859A (en) * 1991-03-20 1992-09-08 Case Western Reserve University Methods of treating interstitial cystitis and urethral syndrome
US5271944A (en) * 1991-04-05 1993-12-21 Biofor, Ltd. Pharmacologically enhanced formulations
US5302397A (en) * 1991-11-19 1994-04-12 Amsden Brian G Polymer-based drug delivery system
ATE135214T1 (de) * 1992-02-17 1996-03-15 Siegfried Ag Pharma Darreichungsformen mit verlaengerter wirkstoffreigabe
IL104192A (en) * 1992-02-17 1998-01-04 Siegfried Ag Pharma Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient
WO1994005262A1 (en) * 1992-09-10 1994-03-17 F.H. Faulding & Co. Limited Sustained release matrix composition
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6726930B1 (en) 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5543099A (en) * 1994-09-29 1996-08-06 Hallmark Pharmaceutical, Inc. Process to manufacture micronized nifedipine granules for sustained release medicaments
US5618845A (en) * 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
DE69739165D1 (de) 1996-07-08 2009-01-29 Penwest Pharmaceuticals Co Matrix mit verzögerter freisetzung für hochdosierte unlösliche arzneistoffe
IT1284604B1 (it) * 1996-09-27 1998-05-21 Roberto Valducci Composizioni farmaceutiche a rilascio controllato per somministrazione orale contenenti nifedipina come sostanza attiva
US5922352A (en) * 1997-01-31 1999-07-13 Andrx Pharmaceuticals, Inc. Once daily calcium channel blocker tablet having a delayed release core
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6485748B1 (en) 1997-12-12 2002-11-26 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
CA2352211C (en) * 1999-09-30 2009-03-24 Edward Mendell Co., Inc. Sustained release matrix systems for highly soluble drugs
MXPA02006324A (es) 1999-12-23 2002-12-13 Pfizer Prod Inc Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco.
IL134701A0 (en) * 2000-02-23 2001-04-30 J P M E D Ltd Homogeneous solid matrix containing vegetable proteins
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
EP1401399A2 (en) * 2001-06-22 2004-03-31 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
DE10142417A1 (de) * 2001-08-31 2003-03-20 Molecular And Clinical Drug Re Arzneimittel
DE10142416A1 (de) * 2001-08-31 2003-03-20 Molecular And Clinical Drug Re Verfahren zur Herstellung von Lösungen
US7429238B2 (en) * 2001-10-15 2008-09-30 The Regents Of The University Of Michigan Systems and methods for the generation of crystalline polymorphs
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
US20040048931A1 (en) * 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
MXPA05008088A (es) * 2003-02-24 2005-09-21 Mallinckrodt Inc Proceso mejorado para preparar benzhidril tioacetamida.
CA2519779A1 (en) * 2003-03-26 2004-10-14 Teva Pharmaceutical Industries Ltd. A process for preparing a pharmaceutical active ingredient with high specific surface area
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
ES2462240T3 (es) * 2006-02-28 2014-05-22 Dart Neuroscience (Cayman) Ltd Piperazinas terapéuticas como inhibidores de PDE4
US20080181966A1 (en) * 2006-10-18 2008-07-31 Cephalon, Inc. Modafinil pharmaceutical compositions
EP2146695A4 (en) * 2007-04-23 2010-05-19 Sun Pharmaceuticals Ind Ltd PHARMACEUTICAL COMPOSITIONS
RU2629843C1 (ru) * 2016-05-24 2017-09-04 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) Способ получения мази нифедипина (варианты)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT629516A (xx) * 1959-04-30
US3920809A (en) * 1973-11-05 1975-11-18 Lilly Co Eli Dibenzo(b,d)pyranone dispersions
US3988439A (en) * 1973-11-05 1976-10-26 Eli Lilly And Company Dibenzo[b,d]pyranone dispersions
DE2400819C2 (de) * 1974-01-09 1982-04-22 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung fester Zubereitungen von schwerlöslichen Arzneimittelwirkstoffen in feinster Verteilung
US4151273A (en) * 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
EP0001247A1 (en) * 1977-09-14 1979-04-04 Kanebo, Ltd. Pharmaceutical preparation containing nifedipine and a method for producing the same.
JPS55129221A (en) * 1979-03-29 1980-10-06 Kaken Pharmaceut Co Ltd Preparation of oral preparation containing hardly soluble medicine
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4311694A (en) * 1979-12-31 1982-01-19 American Cyanamid Company Amorphous coprecipitates of 4-(monoalkylamino) benzoic acid and derivatives and certain water-soluble materials
DE3033919A1 (de) * 1980-09-09 1982-04-22 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung
JPS58116414A (ja) * 1981-12-23 1983-07-11 Yamanouchi Pharmaceut Co Ltd ニカルジピン持続性製剤用球形顆粒およびその製造法
DE3318649A1 (de) * 1983-05-21 1984-11-22 Bayer Ag, 5090 Leverkusen Zweiphasenformulierung
HU198844B (en) * 1984-06-14 1989-12-28 Sandoz Ag Process for producing new galenic pharmaceutical composition ensuring retarded release of active ingredient
IT1178511B (it) * 1984-09-14 1987-09-09 Pharmatec Spa Procedimento per la preparazione di una forma solida per uso orale a base di nifedipina con rilascio
DE3438830A1 (de) * 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
JPS62167727A (ja) 1987-07-24
US4880623A (en) 1989-11-14
GR3003150T3 (en) 1993-02-17
KR870003779A (ko) 1987-05-04
ZA867767B (en) 1987-06-24
EP0220760A3 (en) 1987-09-23
PT83522A (en) 1986-11-01
AU6383286A (en) 1987-04-16
DK481186A (da) 1987-04-16
ES2040209T3 (es) 1993-10-16
NO864060L (no) 1987-04-21
CA1280976C (en) 1991-03-05
FI864151A (fi) 1987-04-16
NO172168B (no) 1993-03-08
JPH0811731B2 (ja) 1996-02-07
ATE66367T1 (de) 1991-09-15
FI87424B (fi) 1992-09-30
KR940006320B1 (ko) 1994-07-16
FI87424C (fi) 1993-01-11
DE3680989D1 (de) 1991-09-26
DK481186D0 (da) 1986-10-08
AU590622B2 (en) 1989-11-09
DK168691B1 (da) 1994-05-24
FI864151A0 (fi) 1986-10-14
NZ217841A (en) 1990-01-29
PT83522B (pt) 1988-11-30
IT8522494A0 (it) 1985-10-15
NO864060D0 (no) 1986-10-13
EP0220760A2 (en) 1987-05-06
EP0220760B1 (en) 1991-08-21
NO172168C (no) 1993-06-16
IT1187751B (it) 1987-12-23

Similar Documents

Publication Publication Date Title
AU590622B2 (en) Process for the preparation of solid nifedipine formulations of high bioavailability and with sustained effect, and formulations thus obtained
CA1269328A (en) Transdermal aqueous aryl-propionic-acid derivatives medication and methods of preparing same
AU1211992A (en) Low dose dry pharmaceutical preparations
HU896191D0 (en) Process for the preparation of pharmaceutical compositions on carrier with increased dissolution
ATE108647T1 (de) Arzneimittel mit langsamer wirkstofffreisetzung.
KR850008279A (ko) 경피투여용 약제의 제조방법
CA1124178A (en) Nabilone granulation
JPS5649314A (en) Lasting pharmaceutical composition having prolonged action and its preparation
JPS5726615A (en) Improving method for absorbability of slightly soluble drug
EP0952819B1 (en) Biologically active composition
JPS62228017A (ja) ジヒドロピリジンを含有する固体の迅速放出性薬剤調製物の製造方法
EP0223033B1 (de) Verfahren zum gleichzeitigen Trocknen und Granulieren von Extraktstoffen aus enteiweisstem Kälberblut, nach diesem Verfahren erhaltenes Granulat und dessen Verwendung zur Herstellung von pharmazeutischen Präparaten
JP3202775B2 (ja) 固形製剤
KR0185294B1 (ko) 투명액상 이부프로펜 조성물 및 이를 함유하는 연질캅셀제
JP2007511517A (ja) 薬剤と照射を受けた賦形剤の製剤の中の薬剤の酸化を最小化
Wisudyaningsih et al. IAI SPECIAL EDITION: Effect of gelling agent and penetration enhancer on the release rate of ibuprofen-PEG 6000 solid dispersion from gel preparations
Sallam et al. Dissolution characteristics of interactive powder mixtures. Part two: effect of surface characteristics of excipients
DE19548367A1 (de) Immunologisch wirksame Mistelextraktzubereitungen
CS234469B1 (cs) Dermální přípravek s obsahem kyseliny vitaminu A
JPS61289033A (ja) ウラシル及び５―フルオロウラシルの直腸投与用製剤

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)